文献速递胸部肿瘤

Mobocertinib治疗EGFR外显子20插入突变经治NSCLC的I/II期试验

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
PubMed 文献 · Cancer Discov · 2021-02-25

该I/II期剂量递增/扩展试验评估了口服EGFR抑制剂Mobocertinib在EGFR外显子20插入突变非小细胞肺癌中的疗效与安全性。剂量递增确定160 mg/d为推荐II期剂量和最大耐受剂量;28例该剂量患者确认缓解率43%(12/28;95%CI 24%-63%),中位缓解持续时间14个月,中位无进展生存7.3个月,安全性与其他EGFR抑制剂一致。

要点

  • Mobocertinib 160 mg/d在EGFRex20ins经治NSCLC中确认缓解率43%(12/28;95%CI 24%-63%)。
  • 中位缓解持续时间14个月,中位无进展生存7.3个月。
  • 最常见任何级别治疗相关不良事件为腹泻83%、恶心43%、皮疹33%、呕吐26%;≥3级仅腹泻21%>5%。

核心结论

  • Mobocertinib在携带多种EGFR外显子20插入变异的经治晚期NSCLC患者中显示出抗肿瘤活性,毒性可控。

研究设计与样本

  • I/II期剂量递增/扩展试验(NCT02716116),剂量递增确定160 mg/d为推荐II期剂量和最大耐受剂量。

主要发现

  • 160 mg/d组136例患者中,最常见任何级别治疗相关不良事件(>25%)为腹泻83%、恶心43%、皮疹33%、呕吐26%,≥3级仅腹泻21%>5%。
  • 28例EGFRex20ins患者接受160 mg/d,研究者评估确认缓解率43%(12/28;95%CI 24%-63%)。
  • 中位缓解持续时间14个月(5.0-未达到),中位无进展生存7.3个月(4.4-15.6)。

关键数值与推荐

  • EGFRex20ins经治NSCLC患者接受Mobocertinib 160 mg/d,确认缓解率43%(12/28;95%CI 24%-63%),中位缓解持续时间14个月(5.0-未达到),中位无进展生存7.3个月(4.4-15.6)。

临床怎么用

  • 对于EGFR外显子20插入突变的经治晚期NSCLC患者,Mobocertinib 160 mg/d可作为潜在口服靶向治疗选择,需关注腹泻等不良反应管理。

局限性

  • EGFRex20ins疗效分析样本量较小(28例),为I/II期试验,尚需进一步开发验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR gene mutations, including exon 20 insertions (EGFRex20ins), in non-small cell lung cancer, was evaluated in a phase I/II dose-escalation/expansion trial (ClinicalTrials.gov NCT02716116). Dose escalation identified 160 mg/d as the recommended phase 2 dose and maximum tolerated dose. Among 136 patients treated with 160 mg/d, the most common any-grade treatment-related adverse events (TRAE; >25%) were diarrhea (83%), nausea (43%), rash (33%), and vomiting (26%), with diarrhea (21%) the only grade ≥3 TRAE >5%. Among 28 EGFRex20ins patients treated at 160 mg/d, the investigator-assessed confirmed response rate was 43% (12/28; 95% confidence interval, 24%-63%) with median duration of response of 14 months (5.0-not reached) and median progression-free survival of 7.3 months (4.4-15.6). Mobocertinib demonstrated antitumor activity in patients with diverse EGFRex20ins variants with a safety profile consistent with other EGFR inhibitors. SIGNIFICANCE: No oral EGFR-targeted therapies are currently approved for patients with EGFRex20ins NSCLC. Mobocertinib demonstrated antitumor activity with manageable toxicity in patients with advanced EGFRex20ins NSCLC in this study, supporting additional development of mobocertinib in this patient population.See related commentary by Pacheco, p. 1617.This article is highlighted in the In This Issue feature, p. 1601.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Riely GJ, Neal JW, Camidge DR, et al. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021. PMID: 33632775. doi:10.1158/2159-8290.CD-20-1598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。